Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | C1R | P00736 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480751 | 0.82 | GABRA1 (0.36) | TAAR1IDO1CYP1A2ALDH1A1HPGD | |
| SCHEMBL7590925 | 0.77 | TAAR1 (0.54) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL533864 | 0.76 | ALDH1A1 (0.47) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29385884 | 0.76 | ALDH1A1 (0.47) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2043471 | 0.74 | — | — | |
| SCHEMBL2139391 | 0.73 | TAAR1 (0.50) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL96154 | 0.73 | GABRA1 (0.45) | TAAR1CYP2D6ALDH1A1MGLLGABRA1 | |
| SCHEMBL7584226 | 0.73 | IDO1 (0.32) | IDO1 | |
| SCHEMBL172963 | 0.72 | — | — | |
| SCHEMBL9317847 | 0.71 | FFAR1 (0.31) | ALDH1A1HPGDGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190131-B1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | UNIV KYOTO (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10414848-B2 | Living radical polymerization initiator, method for producing polymer, and polymer | KYOTO UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| US-20170306073-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | KYOTO UNIVERSITY (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3190131-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | Kyoto University (JP) | 2017-07-12 | — | — | EP | disclosed |
| CN-103237794-B | P2X4Receptor antagonists | 日本化学医药株式会社 | 2016-07-06 | — | — | CN | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5968960-A | ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| US-5804590-A | ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. | SANKYO COMPANY, LIMITED (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| CN-1163105-A | Therapy and prevention for esteoporosis | SANKYO CO (JP) | 1997-10-29 | — | — | CN | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414848-B2 | Living radical polymerization initiator, method for producing polymer, and polymer | CCNY, MTR, PARN | TAAR1 1383/4885IDO1 2108/4885CYP1A2 1673/4885 |
| US-20170306073-A1 | LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER, AND POLYMER | CCNY, MTR, PARN | TAAR1 1383/4885IDO1 2108/4885CYP1A2 1673/4885 |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | TAAR1 2179/4885IDO1 2737/4885CYP1A2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.